Victor Lee joins Pinetree Capital as Chief Investment Officer

M&A Expert Joins the Pinetree Team

Pinetree Capital announces its appointment of Victor Lee as Chief Investment Officer.

METRO MANILA, JANUARY 13, 2019 — Pinetree Capital announces Victor Lee, M&A veteran, as its offices’ Chief Investment Officer. Mr. Lee will oversee an investment strategy involving special purpose vehicles (or SPV funds), which take on explicit objectives per fund.

Mr. Lee is considered an expert in mergers and acquisition finance and brings to Pinetree Capital a worldcass background in international finance and trade. He began his career in finance shortly after graduating from Yale University (BA, Political Science, Cum Laude) and Harvard University (MPP, International Trade & Finance), at Smith Barney, New York City (1993). His professional experiences in New York City during 1990s also include a tenure as Executive Vice President at Bankers Trust, numerous awards from institutions such as Deloitte & Touche, as well as advising several publicly listed companies. Over the years, Mr. Lee has assisted many companies in their initial public offerings (IPO), from managing deal arrangements to architecting fundraising strategies; most recently, he’d assisted Pure Energy Holdings Corporation in putting the company on a path toward IPO.

Today, Victor Lee sees considerable opportunities in Southeast Asia. Putting lessons learned to use — from experiences such as his Series-A fundraise for — for Pinetree Capital, initial areas that he will be integrating heavily will include financial technology, real money gaming, digital therapeutics, and new approaches that challenge the status quo when it comes to social media platforms.

PINETREE CAPITAL is an association of Filipino Family Corporations and Filipino-founded Single Family Offices, with offices in the United States and Southeast Asia.’s investments fall within traditional verticals in real estate, healthcare, and financial services— and in burgeoning spaces, we’ve pursued initiative involving the blockchain and digital therapeutics.